Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in the Treatment of Macular Degeneration

NCT05445063 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT05445063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05445063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium in the Treatment of Macular Degeneration
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
August 31, 2022
Completion date
December 31, 2026
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration